What did @gabynotas1 actually say?
The transcript provided is garbled and does not reflect intelligible speech, so we are working primarily from the video caption. Based on that caption, @gabynotas1 shared that she started Ozempic after getting lab work done, was evaluated by a physician (Dr. Karen Labanda), and received her first "adaptation dose." She stated plainly that this treatment "must ALWAYS be done under medical supervision."
That framing matters. Too many weight-loss influencers position GLP-1 medications as something you self-source and self-administer without clinical oversight. The creator did not do that here. She documented a supervised intake process, including bloodwork and a physician consultation, before starting semaglutide. That is closer to how this class of drugs is supposed to be used than most of what circulates on this platform.
Does the science back this up?
Yes, the general framing holds up. Semaglutide (the active ingredient in Ozempic) has substantial clinical evidence behind it for weight management, though Ozempic is technically approved for type 2 diabetes, not obesity. That distinction is worth knowing.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that semaglutide 2.4 mg weekly produced an average body weight reduction of 14.9% over 68 weeks in adults with obesity or overweight with a weight-related condition. That is a meaningful clinical result. The SUSTAIN trials established efficacy in type 2 diabetes management. The pre-treatment evaluation the creator describes, including lab panels, aligns with standard clinical protocol. Baseline metabolic panels, thyroid function, and kidney function markers are typically assessed before initiating GLP-1 therapy because the drug class carries contraindications including a personal or family history of medullary thyroid carcinoma.
What did they get wrong (or right)?
Credit where it is due: the emphasis on physician evaluation and supervised dosing is accurate and responsible. The "adaptation dose" language also checks out. Starting patients on a lower dose (0.25 mg weekly for semaglutide) before titrating up is standard practice designed to reduce gastrointestinal side effects like nausea and vomiting.
However, one framing issue is worth flagging. The caption describes Ozempic as "a medication that helps with weight loss." That is not wrong in practice, but Ozempic (semaglutide 0.5 mg or 1 mg or 2 mg) is FDA-approved for glycemic control in type 2 diabetes. Wegovy (semaglutide 2.4 mg) is the formulation approved specifically for chronic weight management. Prescribing Ozempic off-label for weight loss is common and legal, but calling it a weight-loss drug without that nuance contributes to confusion that has driven shortages affecting people with type 2 diabetes. A minor point, but worth naming.
What should you actually know?
Semaglutide is not a quick fix, and the research is clear that discontinuation leads to weight regain. Davies et al. (2023, Diabetes, Obesity and Metabolism) found that patients regained approximately two-thirds of their lost weight within a year of stopping the drug. That is not a reason to avoid it, but it is a reason to understand what you are committing to.
Side effects are real and sometimes serious. The most common are gastrointestinal: nausea, vomiting, diarrhea, and constipation. The FDA has also flagged a possible association with gastroparesis. The boxed warning about thyroid C-cell tumors, observed in rodent studies, is another reason the pre-treatment evaluation the creator described matters. Pancreatitis is a rare but documented risk. None of this makes semaglutide dangerous when used appropriately under supervision. It does make the "always under medical supervision" message the creator led with genuinely important, not just a legal disclaimer.
Bottom line
This video does more right than wrong. Starting with lab work, getting a physician evaluation, and beginning at an adaptation dose reflects responsible GLP-1 initiation. The creator is not selling anything dubious here. The main gap is the Ozempic versus Wegovy distinction, which matters for accuracy even if it does not change the clinical picture much for the individual patient. Influencers who document supervised medical processes are doing something more useful than most weight-loss content on this platform.